A phase I trial of weekly docetaxel and cisplatinum combined to concurrent hyperfractionated radiotherapy for non-small cell lung cancer and squamous cell carcinoma of head and neck

Oncology Reports

Volumn 10, Issue 1, 2003, Pages 185-195

  Varveris, Harris A ^a   Mazonakis, M ^b   Vlachaki, M ^a   Kachris, S ^a   Lyraraki, E ^a   Zoras, O ^b   Maris, T ^b   Froudarakis, M ^b   Velegrakis, J ^b   Perysinakis, C ^b   Damilakis, J ^b   Samonis, G ^b  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Cisplatinum; Docetaxel; Hyperfractionated irradiation; Squamous cell carcinoma of the lung head and neck

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; DRUG DERIVATIVE; PACLITAXEL; RADIOSENSITIZING AGENT; TAXOID;

AGED; ARTICLE; CANCER STAGING; CLINICAL TRIAL; FEMALE; HEAD AND NECK TUMOR; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PILOT STUDY; RADIATION DOSE FRACTIONATION; RADIOTHERAPY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PILOT PROJECTS; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY; SURVIVAL RATE; TAXOIDS;

EID: 1842834710     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.10.1.185     Document Type: Article

References (38)

1. Rotman M, Aziz H and Wasserman T: Chemotherapy and Irradiation. In: Principles and Practice of Radiation Oncology. 3rd edition. Perez C and Brady L (eds). Lippincott, 1997.
2. Dewit L: Combined treatment of radiation and cis-diammine dichloroplatinum (II): a review of experimental and clinical data. Int J Rad Oncol Biol Phys 13: 403-426, 1987.
3. Fu K and Phillips T: Biologic rationale of combined radiotherapy and chemotherapy. Hematol Oncol Clin North Am 5: 737-751, 1991.
4. Ringel I and Horwitz SB: Studies with RP-56976 (Taxotere): a semisynthetic analogue of Taxol. J Natl Cancer Inst 83: 288-291, 1991.
5. Chaffey JT and Hellman S: Differing responses to radiation of murine bone marrow stem cells in relation to the cell cycle. Cancer Res 31: 1513-1516, 1971.
6. Hill BT, Whelan RD, Shellard SA, McClean S and Hosking LK: Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro. Invest New Drugs 12: 169-182, 1994. (Pubitemid 24376401)
7. Cerny T, Kaplan S, Pavlidis N, Schoffski P, Epelbaum R, van Meerbeek J, Wanders J, Franklin HR and Kaye S: Docetaxel (Taxotere) is active in non-small cell lung cancer: a phase II trial of the EORTC early clinical trials group (EGTG). Br J Cancer 70: 384-387, 1994.
8. Francis PA, Rigas JR, Kris MG, Pisters KM, Orazem JP, Woolley KJ and Heeian RT: Phase II trial of docetaxel in patients with stage III and IV non-small cell lung cancer. J Clin Oncol 12: 1232-1237, 1994.
9. Dreyfuss AI, Clark JR, Norris CM, Rossi RM, Lucarini JW, Busse PM, Poulin MD, Thornhill L, Costello R and Posner MR: Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 5: 1672-1678, 1996. (Pubitemid 26134226)
10. Catimel G, Verweij J, Mattijssen V, Hanauske A, Piccart M, Wanders J, Franklin H, Le Bail N, Clavel M and Kaye SB: Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 5: 533-537, 1994.
11. Macejewsky B, Taylor J and Withers H: Alpha/beta and the importance of the size of dose per fraction for late complications in the supraglottic larynx. Radiother Oncol 7: 323-326, 1986. (Pubitemid 17232171)
12. Cox JD, Pajak TF, Marcial VA, Hanks GE, Mohiuddin M, Fu KK, Byhardt RW and Rubin P: Dose response for local control with hyperfractionated radiation therapy in advanced carcinomas of the upper aerodigestive tracks: preliminary report of Radiation Therapy Oncology Group protocol: 83-13. Int J Radiat Oncol Biol Phys 2: 34-37, 1990.
13. Horiot JC, Le Fur R, Schraub S, van den Bogaert W, van Glabbeke M, Pierart M and Begg AC: Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Semin Radiat Oncol 1: 34-37, 1992.
14. Cox JD, Azarnia N, Byhardt RW, Shin KH, Emami B and Pajak TF: A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with ≥69.6 Gy in favorable patients with stage III radiation therapy oncology group non-smal cell lung carcinoma - report of RTOG 83-11. J Clin Oncol 8: 1543-1555, 1990. (Pubitemid 20301186)
15. Emami B, Perez CA, Herskovich A and Hederman MA: Phase I/II study of treatment of locally advanced (T3T4) non-oat cell lung cancer with high dose radiotherapy (rapid fractionation): Radiation Therapy Oncology Group study. Int J Radiat Oncol Biol Phys 15: 1021-1025, 1988.
16. Saunders MI, Dische S, Barrett A, Parmar MK, Harvey A and Gibson D: Randomized multicenter trials of CHART vs conventional radiotherapy in head and neck and non-small cell lung cancer. An interim report. Br J Cancer 34: 315-322, 1996.
17. World Health Organization: Handbook for reporting results of cancer treatment. WHO, Geneva, 1979.
18. Peters LJ, Goepfert H, Ang KK, Byers RM, Maor MH, Guillamondegui O, Morrison WH, Weber RS, Garden AS, Frankenthaler RA, et al: Evaluation of the dose for postoperative radiation therapy of the head and neck cancer: first report of a prospective randomized trial. Int J Radiat Oncol Biol Phys 26: 3-11, 1993. (Pubitemid 23137882)
19. Rosell R and Felip E: Role of multimodality treatment for lung cancer. Semin Surg Oncol 18: 143-151, 2000. (Pubitemid 30090455)
20. Uitterhoeve AL, Belderbos JS, Kooien MG, van der Vaart PJ, Rodrigus PT, Benraadt J, Koning CC, Gonzalez Gonzalez D and Bartelink H: Toxicity of high dose radiotherapy combined with daily cisplatin in non-small cell lung cancer: results of the EORTC 08912 phase I/II study. Eur J Cancer 36: 592-600, 2000. (Pubitemid 30156844)
21. Lee JS, Scott C, Komaki R, Fossella FV, Dundas GS, McDonald S, Byhardt RW and Curran WJ Jr: Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable NSCLC: RTOG protocol 91-06. J Clin Oncol 14: 1055-1064, 1996. (Pubitemid 26105509)
22. Jeremic B, Shibamoto Y, Milicic B, Nikolic N, Dagovic A and Milisavljevic S: Concurrent radiochemotherapy for patients with stage III NSCLC: long-term results of a phase II study. Int J Radiat Oncol Biol Phys 42: 1091-1096, 1998. (Pubitemid 29004153)
23. Lee JS, Komaki R, Fossella FV, Glisson BS, Hong WK and Cox JD: A pilot trial of hyperfractionated thoracic radiation therapy with concurrent cisplatin and oral etoposide for locally advanced inoperable NSCLC: a 5-year follow-up report. Int J Radiat Oncol Biol Phys 42: 479-486, 1998. (Pubitemid 28501094)
24. Byhardt RW, Scott CB, Ettinger DS, Curran WJ, Doggett RL, Coughlin C, Scarantino C, Rotman M and Emami B: Concurrent hyperfractionated irradiation chemotherapy for unresectable NSCLC. Results of RTOG 90-15. Cancer 75: 2337-2344, 1995.
25. Byhardt RW, Scott C, Sause WT, Emami B, Komaki R, Fisher B, Lee JS and Lawton C: Response, toxicity, failure patterns, and survival in 5 RTOG trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced NSCLC. Int J Radiat Oncol Biol Phys 42: 469-478, 1998. (Pubitemid 28501093)
26. Komaki R, Scott C, Ettinger D, Lee JS, Fossella FV, Curran W, Evans RF, Rubin P and Byhardt RW: Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable NSCLC. RTOG 92-04. Int J Radiat Oncol Biol Phys 38: 149-155, 1997. (Pubitemid 27270955)
27. Choy H, Devore RF III, Hande KR, Porter LL, Rosenblatt P, Yunus F, Schlabach L, Smith C, Shyr Y and Johnson DH: A phase II study of Paclitaxel, Carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable NSCLC (a Vanderbilt Cancer Center Affiliate Network study). Int J Radiat Oncol Biol Phys 47: 931-937, 2000. (Pubitemid 30345590)
28. Segawa Y, Ueoka H, Kiura K, Kamei H, Tabata M, Sakae K, Hiraki Y, Kawahara S, Eguchi K, Hiraki S and Harada M: A phase II study of Cisplatin and 5-FU with concurrent hyperfractionated thoracic radiation for locally advanced NSCLC: a preliminary report from the Okayama Lung Cancer Study Group. Br J Cancer 82: 104-111, 2000. (Pubitemid 30008967)
29. Adelstein DJ, Lavertu P, Saxton JP, Secic M, Wood BG, Wanamaker JR, Eliachar I, Strome M and Larto MA: Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck. Cancer 88: 876-883, 2000. (Pubitemid 30091108)
30. Schantz S, Harrison L and Forastiere A: Tumors of the nasal cavity and paranasal sinuses, nasopharynx, oral cavity and oropharynx p. 811 in cancer. In: Principles and Practice of Oncology. 6th edition. Lippincott Williams and Wilkins, 2001.
31. Jeremic B, Shibamoto Y, Milicic B, Nikolic N, Dagovic A, Aleksandrovic J, Vaskovic Z and Tadic L: Hyperfractionated radiation therapy with or without concurrent low dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 18: 1458-1464, 2000. (Pubitemid 30205391)
32. Specht L, Larsen S and Hansen H: Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous cell carcinoma of the head and neck. Ann Oncol 11: 845-849, 2000.
33. Furuse K, Kubota K, Kawahara M, Kodama N, Ogawara M, Akira M, Nakajima S, Takada M, Kusunoki Y, Negoro S, et al: Phase II study of concurrent radiotherapy and chemotherapy for unresectable stage III non-small cell lung cancer. J Clin Oncol 13: 869-875, 1995.
34. Ball D, Bishop J, Smith J, Crennan E, O'Brien P, Davis S, Ryan G, Joseph D and Walker Q: A phase III study of accelerated radiotherapy with and without carboplatin in non-small cell lung cancer: an interim toxicity analysis of the first 100 patients. Int J Radiat Oncol Biol Phys 31: 267-272, 1995.
35. Jeremic B, Shibamoto Y, Acimovic L and Djuric L: Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small cell lung cancer. J Clin Oncol 13: 452-458, 1995.
36. Shaw EG, McGinnis WL, Jett JR, Su JQ, Frank AR, Mailliard JA, Engel RE, Wiesenfeld M and Rowland KM Jr: Pilot study of accelerated hyprefractionated thoracic radiation therapy plus concomitant etoposide and cisplatin chemotherapy in patients with unresectable stage III non-small cell carcinoma of the lung. J Natl Cancer Inst 85: 321-323, 1993. (Pubitemid 23068807)
37. Koch WM, Lee DJ, Eisele DW, Miller D, Poole M, Cummings CW and Forastiere A: Chemoradiotherapy for organ preservation in oral and pharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 121:974-980, 1995.
38. Leyvraz S, Pasche P, Bauer J, Bernasconi S and Monnier P: Rapidly alternating chemotherapy and hyperfractionated radiotherapy in the management of locally advanced head and neck carcinoma: four year results of a phase I/II study. J Clin Oncol 12: 1876-1885, 1994. (Pubitemid 24349390)